RMC-6272

RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors[1].

Product Specifications

CAS Number

[2382769-46-0]

Product Name Alternative

RM-006

UNSPSC

12352005

Target

MTOR

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rmc-6272.html

Purity

97.42

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=C(C(F)=C(C=C1)S(CCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCNC(O[C@H]2[C@@H](C[C@@H](CC2)C[C@H]([C@@]3([H])OC([C@@]4([H])N(CCCC4)C(C([C@@]5(O[C@](CC[C@H]5C)([H])C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@H](C([C@@H]([C@@H](/C(C)=C/[C@H]([C@@H](C3)O)C)O)OC)=O)C)C)OC)O)=O)=O)=O)C)OC)=O)=O)(=O)=O)C)N6CC7=CC(C8=CN=C(N)C=C8)=CC=C7OCC6

Molecular Formula

C95H141FN6O27S

Molecular Weight

1850.22

References & Citations

[1]Heng Du, et al. Bi-steric mTORC1-selective inhibitors demonstrate improved potency and efficacy in tumors with mTORC1 hyperactivation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA) : AACR; Cancer Res 2021;81 (13_Suppl) :Abstract nr 1026.